Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine group C conjugate - GlaxoSmithKline

Drug Profile

Meningococcal vaccine group C conjugate - GlaxoSmithKline

Alternative Names: MenC-CRM conjugate vaccine; Meningococcal C-CRM197 conjugate vaccine; Menjugate

Latest Information Update: 25 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Meningococcal group C infections

Most Recent Events

  • 04 Jan 2018 inVentiv Health has merged with INC Research to form Syneos Health
  • 31 Aug 2017 GlaxoSmithKline completes a phase I trial for Meningococcal group C infections (In volunteers) in Germany (IM) (NCT02639351)
  • 01 Mar 2016 GlaxoSmithKline initiates a phase I trial for Meningococcal group C infections (In volunteers) in Germany (IM) (NCT02639351)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top